AlphaMadera's AlphaVal page computes Rallybio Corporation's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag RLYB as undervalued, fairly valued, or overvalued.

What is Rallybio Corporation's fair value?

Fair value for RLYB is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value RLYB?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from RLYB's most recent reported fundamentals.

RLYB - Rallybio Corporation

Price: -- -- | CONSENSUS: Buy DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: RLYB has had negative net income and negative EPS in all 5 available fiscal year(s). Quality gate: persistently unprofitable companies are excluded.